| Literature DB >> 24189375 |
Maja Segvić Klarić1, Dubravka Rašić, Maja Peraica.
Abstract
Ochratoxin A (OTA) is a nephrotoxic mycotoxin with carcinogenic properties. Its presence was detected in various foodstuffs all over the world but with significantly higher frequency and concentrations in areas with endemic nephropathy (EN). Even though food is often contaminated with more than one mycotoxin, earlier studies focused on the occurrence and toxicology of only OTA. Only a limited number of surveys showed that OTA co-occurs in food with mycotoxins (citrinin-CIT, penicilic acid, fumonisin B1-FB1, aflatoxins-AF) which exert nephrotoxic, carcinogenic or carcinogen-promoting activity. This review summarises the findings on OTA and its co-occurrence with the mentioned mycotoxins in food as well as experimental data on their combined toxicity. Most of the tested mycotoxin mixtures involving OTA produced additive or synergistic effects in experimental models suggesting that these combinations represent a significant health hazard. Special attention should be given to mixtures that include carcinogenic and cancer-promoting mycotoxins.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24189375 PMCID: PMC3847710 DOI: 10.3390/toxins5111965
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Recent data on mycotoxin mixtures involving ochratoxin A (OTA) in foods from European countries.
| Sample/No (Country) | Mycotoxin | Contamination (%) | Range (μg·L−1 or µg·kg−1) | Co-occurrence | Reference | |||
|---|---|---|---|---|---|---|---|---|
| Beer/106 (25 EU)a | AF | Nd | - | Two toxins | [ | |||
| DON | 66 | <0.5–18.6 | 41.5% | |||||
| FB1 | 96 | <0.1–30.3 | Three toxins | |||||
| FB2 | 57 | <0.1–3.9 | 42.4% | |||||
| OTA | 66 | <0.002–0.189 | ||||||
| Spices/105 (Turkey) | AF | 21.1–79.2 | 0.13–37.38 | 4.3%–62.5% | [ | |||
| OTA | 17.4–75 (6.7% > EU limit for both toxins) | 0.06–98.2 | ||||||
| Cereals/110 Turkey | AF | 24.5 | 0.022–0.233 | 14.6% | [ | |||
| OTA | 43.6 | 0.066–1.125 | ||||||
| Baby milk/62 (Turkey) | AFM1 | 8 | 0.06–0.022 | 1.6% | [ | |||
| OTA | 19,4 | 0.017–0.184 | ||||||
| Food b/345 (Italy) | AF | 5 (1.2% > EU limit) | 0.33–70.69 | Not specified | [ | |||
| OTA | 17.6 | 2.76–23.7 | ||||||
| Pasta/27 (Italy) | AFB1 | Nd | Not specified | [ | ||||
| DON | 81.5 (26% > EU limit) | 35.1–450.0 | ||||||
| OTA | 96.3 | 0.2–0.52 | ||||||
| Breakfast Cereals/46 (Spain) | AF | 19 | 0.04 c | Two toxins 28% | [ | |||
| OTA | 5 | 0.03 | ||||||
| ZEA | 43 | 2.87 | ||||||
| Barley/123 (Spain) | AF | 100 | 0.15 c | Two or three | [ | |||
| OTA | 58 | 0.06 | toxins 80% | |||||
| ZEA | 39 | 0.84 | ||||||
| Wheat/37 Oat bran/30 (Spain) | DON | 62/17 (total of 19% > EU limit) | 1308/230c | Two toxins 10.5% | [ | |||
| OTA | 30/20 | 1.1/0.3 | ||||||
| ZEA | 13/17 | 8/8 | ||||||
| Cereals and cereal-based food/265 (Mediterranean region) d | AFs | 10 (8% AFB1 > EU limit) | 4.2–66.7 | Two toxins 14%> two toxins 18% | [ | |||
| BEA | 10 | 2.4–844 | ||||||
| DAS | 2.8 | 6.4–97 | ||||||
| DON | 4.5 | 63.2–296 | ||||||
| FB1 | 3 | <LOQ-186 | ||||||
| FB2 | 3.3 | <LOQ-176 | ||||||
| HT-2 | 4.5 | <LOQ-87 | ||||||
| NIV | 50 | 100–903 | ||||||
| OTA | 1.8 (All > EU limit) | 75–112 | ||||||
| T-2 | 5 | 12.9–78.4 | ||||||
| Fermented meat/90 (Croatia) | AFB1 | 10 | <1.0–3.0 | Not specified | [ | |||
| OTA | 64.4 | <0.05–7.83 | ||||||
| CIT | 4.4 | <1.0–1.0 | ||||||
Notes: a: 25 European countries; b: Food imported in Italy (nuts, nut products, dried fruits, cereals, cereal products, pulses, dried vine fruits, coffee);c: Results are represented as mean concentration; d: Italy, Spain, Tunisia, Morocco; Nd- not detected.
In vivo and in vitro interactions of OTA with CIT, PA, FB1 or AFB1.
| Experimental model | Mycotoxin combination/treatment | Effect (Interactions) | References |
|---|---|---|---|
| Opossum kidney cells | OTA + CIT (0.5–50 µM): | [ | |
| concentrated OTA < concentrated CIT; | ↓Cytotoxicity (AN) | ||
| concentrated OTA ≤ concentrated CIT | ↑Cytotoxicity (A) | ||
| OTA (10 µM) + CIT (50 µM) | ↑DNA adducts | ||
| Human kidney cells (HK2) | OTA + CIT | ↑DNA adducts | [ |
| Porcine urinary bladder cells | OTA (0.001–1 μM) + CIT (0.001–1 μM)/24 h | No effect on viability | [ |
| V79 cells | OTA (1–10 μM) + CIT (1–10 μM)/24 h | No effect on viability | [ |
| PK15 cells | OTA (6 and 10 µM)+ CIT (30 and 50 μM)/24 h | ↑cytotoxicity (A) | [ |
| Human proximal tubule cells | OTA (25 and 50 nm·L−1) + CIT (0.25 and 1 μmol·L−1)/24 h | No effect on caspase-3 activation | [ |
| OTA (25 and 50 nmol·L−1) + CIT (2.5 and 5 μmol·L−1) | ↓caspase-3 (AN) | ||
| OTA (25 and 50 nmol·L−1) + CIT (7.5 and 15 μmol·L−1) | ↑;caspase-3 (A) | ||
| PK15 cells | OTA (30 and 50 μM) + CIT (6 and 10 μM)/12 and 24 h | ↑apoptosis (S) | [ |
| Vero cells | OTA (12.5 and 25 μM) + CIT (60 μM)/12 h | ↓cell viability (S) | [ |
| Rat | OTA (0.125 mg·kg−1 21 d, p.o.) + CIT (20 mg·kg−1 p.o.) | ↑plasma MDA level | [ |
| Rat | OTA (26 μg·kg−1 feed) + CIT (100 μg·kg−1 feed) for 21 d | ↑kidney OTA-DNA adduct formation (S) | [ |
| S. | OTA (12.3–1000.0 μg/plate) + CIT (3.0–250.0 μg/plate) | No increased mutagenicity | [ |
| Chicken embryos | OTA (0.03–0.5 μg/embryo) + CIT (4 μg/embryo) | No increased teratogenicity | [ |
| Pregnant rats | OTA (1 mg·kg−1) + CIT (30 mg·kg−1)/1 × s.c. | ↑fetal malformations | [ |
| Chicken | OTA (0.5 mg·kg−1 b.m. for 2 d, i.m.) + CIT (25 mg·kg−1 infusion) | No effect on diuresis | [ |
| Broiler chicks | OTA (3.0 mg·kg−1 feed) + CIT (300 mg·kg−1 feed) 21 d | No effect on plasma constituents | [ |
| Rabbits | OTA (0.75 mg·kg−1 feed) + CIT (15 mg·kg−1 feed) 60 d | ↑ ultrastructural kidney changes | [ |
| Dogs | OTA (0.1 and 0.2 mg·kg−1 b.m) p.o. + CIT (5 kg−1 b.m)/i.p. 14 d | Kidney necrosis | [ |
| Human PBM | OTA (0.0038–12.5 mg·L−1) + mixture PA + CIT + FB1 (0.038–125 mg·L−1)/24 h | No effect on metabolic activity (AN) | [ |
| Chickens | OTA 0.1 mg·mL−1 + PA 6 mg·mL−1/gastric intubation 20 and 28 d | ↑mortality (S) | [ |
| Chickens | OTA (0.13–0.8 mg·kg−1 feed) + PA (1–2 mg·kg−1 feed)/6–10 weeks | ↓body weight, | [ |
| Mice | OTA (10 mg·kg−1 feed) + PA (40 mg·kg−1 feed)/10 d | ↑mortality, acute multifocal toxic tubular nephrosis (S) | [ |
| Pigs | OTA (0.09–0.79 mg·kg−1 feed) + PA (1–9 mg·kg−1 feed)/3–5 months | ↑degenerations in kidney proximal tubules and proliferation in the interstitium (S) | [ |
| Human PBM | OTA (0.0038–12.5 mg·L−1) + mixture CIT + FB1 (0.038–125 mg·L−1)/24 h | ↑cytotoxicity (S) | [ |
| C6 glioma cells, Caco-2 and Vero cells | OTA (10 µM) + FB1 (5, 25 and 50 µM)/24–72 h | ↑cytotoxicity (S) | [ |
| PK15 cells | OTA (0.05, 0.5 and 5 µg·mL−1) + FB1 (0.05, 0.5 and 5 µg·mL−1)/24 h | ↑cytotoxicity, lipid peroxidation and micronuclei (AD); | [ |
| Turkey poults | OTA (3 mg·kg−1 feed) + FB1 (300 mg·kg−1 feed)/3 weeks | ↓body weight, ↑AST, ALT, creatinine (S); serum triglycerides (AN) | [ |
| Rabbits | OTA (2 mg·kg−1 feed) + FB1 (10 mg·kg−1 feed)/45 d | ↑ALP (AD); ↑AST, ALT (LAD) | [ |
| Rats | OTA (5 ng·kg−1, 0.05, 0.5 mg·kg−1) + FB1 (200 ng·kg−1, 0.05, 0.5 mg·kg−1)/p.o. 15 d | ↑lipid peroxidation, protein carbonyls, DNA damage in the kidneys (S); ↓ catalase (S); ↑DNA adducts (S) | [ |
| Pigs | OTA (0.5 mg·kg−1 feed) + FB1 (10 mg·kg−1 feed)/35–49 d | ↑kidney damage, AST, ALT, creatinine (S); ↓ antibody titer against the Morbus Aujeszky (S) | [ |
| Vero cells | OTA + AFB1 (5–50 µM)/24 hOTA (1 µM) + AFB1 (1–20 µM)OTA (1–20 µM) + AFB1 (1 µM) | ↑cytotoxicity (A) | [ |
| HepG2 cells | OTA 1–200 µM + AFB1 (100 or 150 µM)/24 h | ↑cytotoxicity (AD); | [ |
| Rats | Single doses OTA 0.5 mg·kg−1 + AFB1 0.25 mg·kg−1 p.o. | No interactions in acute liver toxicity, kidney or immunological organs damage | [ |
Notes: COX2: cycloxygenase; PMB: peripheral blood mononuclear cells; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; S: synergism; AD: additive; LAD: less than additive; AN: antagonism.
Figure 1Interactions of mycotoxin combinations involving OTA and their possible role in the development of chronic renal diseases and cancer following chronic exposure to subtoxic concentrations of mycotoxin mixtures.